C-MER Medical Holdings Limited (Stock Code: 03309) disclosed a repurchase of 200,000 shares on 10 November 2025, executed on the Hong Kong Stock Exchange at a highest price of HKD 1.82 and a lowest price of HKD 1.80. The shares are held as treasury shares, increasing treasury shares to 15,288,000 from 15,088,000.

After this transaction, 1,240,272,870 shares remain issued and outstanding (excluding treasury shares), and total issued shares remain 1,255,560,870. The moratorium period on new share issues or treasury share sales or transfers following this repurchase extends until 10 December 2025.

The announcement also outlines earlier buybacks from July 2024 through May 2025, which are earmarked for cancellation but not yet canceled. As stated in the disclosure, the repurchase mandate was approved on 19 May 2025, authorizing up to 125,556,087 shares for repurchase. To date, repurchases under this authorization represent 0.0161% of the company’s total shares at the time of the mandate.